| Miguel Martín, Hospital General Universitario Gregorio Marañón, Madrid, Spain |
| Chair: Ángel Guerrero, Instituto Valenciano de Oncología (IVO), Valencia, Spain |
|
| 16:45 - 17:05 | Bispecific antibodies for cancer treatment Rakesh Kumar, Swami Rama Himalayan University, Dehradun, India |
| 17:05 - 17:25 | Predicting efficacy of adjuvant bisphosphonates in breast cancer Roger Gomis, Institución Catalana de Investigación y Estudios Avanzados (ICREA), Barcelona, Spain |
| 17:25 - 17:45 | Advances in antibody-drug conjugates Erika Hamilton, Sarah Cannon Research Institute, Nashville, USA |
| 17:45 - 18:00 | Discussion |
| Chair: Luis Costa, Hospital de Santa María, Lisbon, Portugal |
|
| 18:15 - 18:35 | Adjuvant therapy in luminal early breast cancer: recent advances and on going trials Miguel Martín, Hospital General Universitario Gregorio Marañón, Madrid, Spain |
| 18:15 - 18:35 | Neoadjuvant therapy for triple negative operable breast cancer: current status and ongoing trials Peter Schmid, Barts Cancer Institute, London, UK |
| 18:55 - 19:15 | Neoadjuvant therapy for HER2-positive breast cancer: ongoing studies Sara Tolaney, Dana-Farber Cancer Institute, Boston, USA |
| 19:15 - 19:30 | Discussion |